基于网络药理学预测黄甲软肝颗粒抗肝纤维化作用及验证研究

doi:10.3969/j.issn.1000-8535.2022.06.024

广州医药 ›› 2022, Vol. 53 ›› Issue (6): 119-127.DOI: 10.3969/j.issn.1000-8535.2022.06.024

基于网络药理学预测黄甲软肝颗粒抗肝纤维化作用及验证研究

蔡强¹, 张苗¹, 黄朝情², 张荣¹, 杨蕾¹, 王宗权³

1 广州中医药大学(广州 510000)
2 北京盈科瑞药物研究院有限公司(北京 100000)
3 盈科瑞(横琴)药物研究院有限公司,国家中药现代化工程技术研究中心新型递药系统分中心,广东省雾化吸入制剂工程技术研究中心(珠海 519000)

收稿日期:2021-08-19 出版日期:2022-11-20 发布日期:2022-11-30
通讯作者: 王宗权,E-mail: wzq03yjs@163.com
基金资助:
广东省重点领域研发计划项目(2019B020201006);国家“重大新药创制”科技重大专项项目(2017ZX 09301017);首届中国横琴科技创业大赛项目

Prediction of anti-hepatic fibrosis effect of Huangjia Ruangan Granules based on pharmacology network and its verification

CAI Qiang¹, ZHANG Miao¹, HUANG Chaoqing², ZHANG Rong¹, YANG Lei¹, WANG Zongquan³

1 Guangzhou University of Chinese Medicine, Guangzhou 510000,China
2 Beijing Yingkerui Pharmaceutical Institute Co.,Ltd, Beijing 102200, China
3 Yingkerui (Hengqin) Pharmaceutical Research Institute Co., Ltd, New Drug Delivery System Sub Center of National Research Center for Modern Engineering and Technology of Traditional Chinese Medicine, Engineering Technology Research Center of Guangdong Aerosol Inhalation Preparation, Zhuhai 519000, China

Received:2021-08-19 Online:2022-11-20 Published:2022-11-30

摘要/Abstract

摘要： 目的利用网络药理学技术,分析黄甲软肝颗粒治疗肝纤维化的作用网络,以及黄甲软肝颗粒治疗肝纤维化的潜在作用机制,并在体内动物实验进行初步验证。方法采用中药系统药理学分析平台中寻找黄甲软肝颗粒中10味中药相关的化学成分和作用靶点,通过GeneCards等数据库筛选肝纤维化疾病相关的靶标;对药物与疾病靶点相映射得到黄甲软肝颗粒治疗肝纤维化的作用靶点,运用cytoscape将疾病靶点与复方活性成分靶点的交集-交集部分对应的活性成分”构建“C(成分)-T(靶点)”作用网络。将交集靶点利用 DAVID数据库进行GO富集分析和KEGG富集分析,以获得其潜在作用机制。最后,通过黄甲软肝颗粒防治CCl₄导致SD大鼠肝纤维化的体内实验进行初步验证,考察末次给药后大鼠体质量和肝脏指数,采用微板法检测SD大鼠血清中天冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)水平,苏木精-伊红染色观察肝脏病理学变化。结果预测筛选得到黄甲软肝颗粒共有117个潜在活性成分,266个活性成分对应靶点,161个交集靶点,关键成分有槲皮素、山奈酚、丹参酮IIA、芒柄花黄素等,关键靶点有PTGS2、PTGS1、NCOA1、ACHE、HTR、RXRA、ADRB2、IL1B等。GO 分析共包含 960条富集结果,其中生物过程845 条,分子功能 63条,细胞组成 52 条;KEGG 分析共得出68条通路,与本次研究较相关的通路主要包括TNF信号通路、Toll样受体信号通路、Rap1信号通路、胞质DNA传感途径、ErbB信号通路、VEGF信号通路等。体内动物实验研究表明,黄甲软肝颗粒能显著降低大鼠的肝脏指数和血清ALT、AST,改善肝组织病理学指标。结论黄甲软肝颗粒可通过多成分、多途径、多靶点协同发挥治疗肝纤维化的作用,本研究为黄甲软肝颗粒治疗肝纤维化疾病的物质基础、作用机制及临床应用的进一步研究奠定基础。

关键词: 网络药理学, 黄甲软肝颗粒, 肝纤维化, 作用机制, 槲皮素

Abstract: Objective To analyze the effective network of Huangjia Ruangan Granules in treating liver fibrosis and its potential mechanism by using network pharmacology, and preliminary verify by animal in vivo experiments. Methods From the Chinese Medicine System Pharmacology Analysis Platform, we searched for the chemical constituents and targets of 10 Chinese herbs in Huangjia Ruangan Granules, and screened the targets related to liver fibrosis diseases through GeneCards and other databases. The drug and disease target were mapped to the target of Huangjia Ruangan Granules for the treatment of liver fibrosis, and the active component corresponding to the intersection of the disease target and the compound active component target was constructed using cytoscape “C (component)-T (target)” action network. The intersection target was used for GO enrichment analysis and KEGG enrichment analysis with DAVID database to obtain its potential mechanism of action. Finally, through the in vivo experiment of using Huangjia Ruangan Granules to prevent and treat CCl₄ leaded liver fibrosis in SD rats, the rats' body weight and liver index after the last dose were recorded, and the levels of aminotransferase (AST) and alanine aminotransferase (ALT) in the serum of SD rats were detected by the microplate method, hematoxylin-eosin staining were used to observe liver pathological changes. Results Predictive screening showed that Huangjia Ruangan Granules had 117 potential active ingredients, 266 active ingredients corresponded to targets, and 161 intersection targets. The key ingredients was quercetin, kaempferol, tanshinone IIA, formononetin, etc. The key targets were PTGS2, PTGS1 NCOA1, ACHE, HTR, RXRA, ADRB2, IL1B, etc. GO analysis showed a total of 960 enrichment results, including 845 biological processes, 63 molecular functions, and 52 cell compositions; KEGG analysis revealed a total of 68 pathways, the related pathways included TNF signaling pathway, Toll-like receptor signaling pathway, Rap1 signaling pathway, cytoplasmic DNA sensing pathway, ErbB signaling pathway and VEGF signaling pathway, etc. In vivo animal experiments had shown that Huangjia Ruangan Granules could significantly reduce the liver index and serum ALT and AST levels of rats, and improve liver histopathological indicators. Conclusions Huangjia Ruangan Granules treated liver fibrosis through multi-component, multi-pathway and multi-target synergy. This research laid the groundwork for the material basis, mechanism and clinical application of Huangjia Ruangan Granules in treating liver fibrosis diseases.

Key words: network pharmacology, Huangjia Ruangan Granules, liver fibrosis, mechanism of action, quercetin

蔡强, 张苗, 黄朝情, 张荣, 杨蕾, 王宗权. 基于网络药理学预测黄甲软肝颗粒抗肝纤维化作用及验证研究[J]. 广州医药, 2022, 53(6): 119-127.

CAI Qiang, ZHANG Miao, HUANG Chaoqing, ZHANG Rong, YANG Lei, WANG Zongquan. Prediction of anti-hepatic fibrosis effect of Huangjia Ruangan Granules based on pharmacology network and its verification[J]. Guangzhou Medical Journal, 2022, 53(6): 119-127.

参考文献

[1] MANNING D S, AFDHAL N H. Diagnosis and quantitation of fibrosis[J]. Gastroenterology, 2008, 134(6): 1670-1681.
[2] 杨凤蕊, 娄建石, 方步武. 蒿鳖养阴软坚方抗CCl₄复合因素所致大鼠肝纤维化的作用[J]. 中草药, 2011, 42(3): 530-534.
[3] 康玉华, 杨宇, 王宝家, 等. 肝纤维化动物模型的研究进展[J]. 辽宁中医杂志, 2016, 43(10): 2229-2231.
[4] PINZANI M, ROMBOUTS K. Liver fibrosis: from the bench to clinical targets[J]. Dig Liver Dis, 2004, 36(4): 231-242.
[5] ZHANG L, SCHUPPAN D. Traditional Chinese Medicine (TCM) for fibrotic liver disease: hope and hype[J]. J Hepatol, 2014, 61(1): 166-168.
[6] WANG Y, XIAO J, SUZEK T O, et al. PubChem: a public information system for analyzing bioactivities of small molecules[J]. Nucleic Acids Res, 2009(37): 623-633.
[7] 刘梦, 吴凤芝, 张蔚, 等. 基于网络药理学的四逆散与酸枣仁汤治疗失眠分子机制的比较研究[J]. 北京中医药大学学报, 2019, 42(1): 44-51.
[8] AMBERGER J S, BOCCHINI C A, SCHIETTECATTE F O, et al. OMIM.org: Online Mendelian Inheritance in Man, an online catalog of human genes and genetic disorders[J]. Nucleic Acids Res, 2015(43):D789-798.
[9] HUANG D W, SHERMAN B T, LEMPICKI R A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources[J]. Nat Protoc, 2009, 4(1):44-57.
[10] WEISKIRCHEN R. Hepatoprotective and anti-fibrotic agents: it's time to take the next step[J]. Front Pharmacol, 2016(6):303.
[11] TACKE F, WEISKIRCHEN R. An update on the recent advances in antifibrotic therapy[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(11): 1143-1152.
[12] TAPPER E B, LOK A S. Use of liver imaging and biopsy in clinical practice[J].N Engl J Med,2017,377(8):756-768.
[13] LONG M T, ALISON P, MASSARO J M, et al. The association between non-invasive hepatic fibrosis markers and cardiometabolic risk factors in the Framingham heart study[J]. PLoS One, 2016,11(6):157-158.
[14] WANG S, WANG Y, LIU X, et al. Anti-inflammatory and anti-arthritic effects of taraxasterol on adjuvant-induced arthritis in rats[J]. J Ethnopharmacol,2016(187):42-48.

基于网络药理学预测黄甲软肝颗粒抗肝纤维化作用及验证研究

Prediction of anti-hepatic fibrosis effect of Huangjia Ruangan Granules based on pharmacology network and its verification

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 4

编辑推荐

Metrics

本文评价

[1]	黄迪, 黄宇, 黄子圣, 翁杰锋, 李佩霖, 张帅, 古维立. 逆转素对胆管结扎诱导大鼠肝损害的影响[J]. 广州医药, 2021, 52(3): 9-17.
[2]	梁学玲, 秦艳虹. 基于网络药理学分析重用生白术组方治疗小儿功能性便秘的作用机制[J]. 广州医药, 2020, 51(5): 84-89.
[3]	谢巍, 杨妮, 肖萍. 基于网络药理学预测银杏叶治疗心肌缺血的作用机制[J]. 广州医药, 2020, 51(1): 32-38.
[4]	张强, 黄迪, 黄宇, 麦振豪, 张汉意, 张帅, 李宁, 翁杰锋, 古维立. Reversine对人肝星状细胞系LX-2凋亡的影响[J]. 广州医药, 2017, 48(1): 59-62.